Type 2 immunity in allergic diseases

Cellular and Molecular Immunology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 17, 2025

Язык: Английский

---

Thymus and activation-regulated chemokine (CCL17) as a clinical biomarker in atopic dermatitis: significance and limitations in the new treatment era

Frontiers in Allergy, Год журнала: 2025, Номер 5

Опубликована: Янв. 23, 2025

Thymus and activation-regulated chemokine (TARC; CCL17) is a T-helper-2 that reflects atopic dermatitis (AD) disease activity. Since 2008, serum TARC levels have been commercially measured in Japan, clinical experience has shown the usefulness of TARC. The fallacy eczema always visible often hinders successful treatment, when there subclinical inflammation which inferable from level. AD treatment entered new era with higher therapeutic efficacy. different meaning than it did previously, its significance limitations are discussed. First, more appropriate topical therapy monitoring would be useful selecting truly necessitated patients for expensive therapies. Dupilumab quickly lowers before improvement, normalization not criterion dose reduction. However, some severe cases, may help determine whether to continue treatment. During JAK inhibitors, elevated abnormally high, leading exacerbation dermatitis. Prurigo nodularis divided into two types associated normal levels, aid selection agents. In this era, remains biomarker accurate drug determination efficacy; Currently, trials AD, all outcome measurements depend on score; however use biomarker, such as TARC, secondary measure will clarify characteristics each pathophysiological conditions expected effective.

Язык: Английский

---

Effects of Tralokinumab on Clinical and Laboratory Indexes in Atopic Dermatitis: A 24-Week Real-World Study

Dermatitis, Год журнала: 2024, Номер unknown

Опубликована: Окт. 3, 2024

Tralokinumab, a monoclonal anti-IL-13 antibody, is approved for treating atopic dermatitis (AD). Real-world data on its effectiveness and safety are limited.

Язык: Английский

---

Biologic and Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Mechanistic Considerations

Journal of Allergy and Clinical Immunology, Год журнала: 2024, Номер 154(1), С. 20 - 30

Опубликована: Апрель 24, 2024

Язык: Английский

---

Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment

American Journal of Clinical Dermatology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 16, 2025

Atopic dermatitis (AD) is a chronic, inflammatory skin disease that can significantly affect quality of life. Presence, severity, and therapeutic response AD are traditionally reported through clinical assessments including the Eczema Area Severity Index or Investigator's Global Assessment. These rating scales visual used in trials to denotate severity. Alternatively, biomarkers open potential further enhance diagnosis AD, assess status potentially enable tailored treatment options for patients. Biomarkers be classified according their use, presentation, underlying/endogenous molecular mechanisms. Specifically, interleukin (IL)-13, which has been shown key biomarker pathogenesis, prediction development monitor severity/response treatment. Treatment with tralokinumab, human monoclonal antibody binds directly to—and subsequently blocks signaling of—IL-13, reduce inflammation, re-balance microbiome, improve barrier patients AD. In this review, AD-related biomarkers, role IL-13 driving impact inhibition by tralokinumab on other discussed.

Язык: Английский

---

Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study

Dermatology and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Янв. 25, 2025

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and relapsing course, affecting approximately 25% of children 4–7% adults. This study evaluated the efficacy, safety, quality-of-life impact tralokinumab, humanized monoclonal antibody targeting interleukin-13 (IL-13), in treating moderate-to-severe AD real-world setting, with focus on different phenotypes. An observational cohort 30 adults treated tralokinumab for ≥ 16 weeks was analyzed. Clinical demographic data were collected, outcomes assessed using Eczema Area Severity Index (EASI), Dermatology Life Quality (DLQI), numeric rating scales (NRS) sleep disturbances. By week 16, 60% achieved 75% improvement EASI (EASI75) 31% reached 90% (EASI90), reflecting substantial clinical improvements. A 4-point reduction NRS observed 63% patients increasing to 70% 32. Similarly, significant improvements disturbance sustained effects through Subgroup analysis revealed superior responses early-onset atopic comorbidities. Lower total immunoglobulin E (IgE) levels at correlated better outcomes, suggesting IgE as potential biomarker. 32, had DLQI ≤ 5, indicating minimal impact. Additionally, 88% least one therapeutic target, 81% met composite endpoints combining clinician-assessed patient-reported outcomes. The safety profile consistent trials, mild conjunctivitis injection site reactions most common adverse events. These findings support an effective well-tolerated treatment, emphasizing importance phenotype-specific approaches management.

Язык: Английский

---

Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice

Annals of Dermatology, Год журнала: 2025, Номер 37

Опубликована: Янв. 1, 2025

Atopic dermatitis (AD) is a chronic eczematous disorder characterized by intense itchiness. Systemic therapies for AD include Janus kinase (JAK) inhibitors and various biological agents. The effects of transitioning from the JAK1 inhibitor, upadacitinib, to anti-interleukin 13 antibody, tralokinumab, remain unclear. This study evaluated transition 15 mg upadacitinib tralokinumab in patients with moderate-to-severe AD. analysis included 20 who switched due an inadequate response or adverse events (AEs). We assessed total regional eczema area severity index (EASI), which assessments head neck, trunk, upper lower limbs, along erythema, edema/papulation, excoriation, lichenification, peak pruritus numerical-rating scale (PP-NRS), initially (start upadacitinib), at point (week 0), during follow-up weeks 4 12. EASI, EASI four anatomical regions, clinical manifestations significantly declined baseline 12, no substantial reductions week 0. PP-NRS score notably decreased 4. Achieving 50 75 improved post-switching. Transitioning substantially alleviated rash experienced suboptimal responses AEs upadacitinib.

Язык: Английский

---

Systemtherapie der AD

hautnah dermatologie, Год журнала: 2025, Номер 41(S1), С. 6 - 15

Опубликована: Фев. 1, 2025

---

Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years

American Journal of Clinical Dermatology, Год журнала: 2025, Номер unknown

Опубликована: Март 14, 2025

There is a need for long-term atopic dermatitis (AD) treatments that can effectively improve AD involvement of the head and neck (H&N) region (referred to as H&N AD). Tralokinumab, high-affinity monoclonal antibody neutralizes interleukin-13, approved treatment moderate-to-severe AD. Recent real-world studies have observed effectiveness tralokinumab Here, data from phase III parent trials, ECZTRA 1 2, extension trial, ECZTEND, were used assess impacts on association between improvements in patient quality life, evaluate whether proportion patients developed paradoxical erythema. These post hoc analyses included all initiated or 2. Patients treated up 4 years (i.e., 52 weeks 2 plus 152 ECZTEND). Outcomes body subscores Eczema Area Severity Index (EASI; H&N, upper limbs, trunk, lower limbs) Dermatology Life Quality (DLQI). Correlations EASI DLQI assessed with Spearman's correlation coefficient (ρ). The incidence erythema (defined increasing baseline score 3, while other regional are 0 1, during two more consecutive visits) was also assessed. Overall, 1192 who whom 523 opted continue analyzed. Percentages had ≤ increased 12.2% at trial 87.2% by week ECZTEND. Improvements subscore outcomes comparable across regions throughout timepoints study. At 16, moderately correlated total (ρ = 0.47), strongest numerical correlations questions regarding skin discomfort 0.43) embarrassment due 0.40). During treatment, seven tralokinumab-treated exhibited erythema, five improved absent mild continued treatment. Tralokinumab provided progressive sustained AD, 0/1 nearly 90% years. similar associated particularly self-consciousness/embarrassment skin. NCT03131648 (ECZTRA 1); study start date: 30 May, 2017; primary completion 7 August, 2018; 10 October, 2019. NCT03160885 2); 12 June, September, 2019; 14 NCT03587805 (ECZTEND); 18 March, cut-off April, 2022; 3 July, 2024; 2024. an injectable capable providing disease control region. Atopic chronic affect multiple areas. occurring AD) be especially burdensome owing part its high visibility. Additionally, challenging treat may show clinical response than Therefore, there demand provide complete/almost complete clearance, around face. medication treating It has been shown settings. trials 2) (ECZTEND), funded LEO Pharma A/S, examine impact adults We found severity including facial redness erythema), Worsening new sometimes certain treatments. Very few showed specific compared sites. Most these cases resolved findings treats

Язык: Английский

---

T cells promote distinct transcriptional programs of cutaneous inflammatory disease in keratinocytes and dermal fibroblasts

Journal of Investigative Dermatology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

---